This page shows the latest Hal Barron news and features for those working in and with pharma, biotech and healthcare.
GSK’s CEO Emma Walmsley and R&D chief Hal Barron have led the company’s re-entry into oncology, having overseen a number of new additions to the oncology pipeline.
We believe a once-daily single inhaler triple therapy that improves lung function is an advance for patients with uncontrolled asthma since this option is not currently available,” said Hal Barron,
It’s another example of GSK expanding its oncology pipeline under new R&D chief Hal Barron, which has already seen its portfolio double to 17 clinical-stage projects since he ... Barron has said Zejula is one of three that he expects to drive the
ago. GSK’s new CEO Emma Walmsley (pictured left) and new R&D chief Hal Barron have helmed the company’s re-entry into oncology, having overseen a number of new
GSK can't catch up with immunotherapy leaders, such as Merck &Co’s Keytruda and Bristol-Myers Squibb’s Opdivo, but its R&D chief Hal Barron (pictured right) has still ... Barron has also indicated GSK’s interest in cell and gene therapies, which is
Results are expected in 2021. “We believe this drug has the potential to transform the treatment landscape for patients with [these infections] who currently have limited therapeutic options,” commented Hal Barron
More from news
Approximately 1 fully matching, plus 51 partially matching documents found.
Walmsley has impressed with a few high-profile hirings to key positions, including Dr Hal Barron as its new R&D supremo, but it will take a few years to see
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
years. Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. ... Sin will report to Hal Barron and will be based at the group’s San Francisco office.
He has served as CEO at Calico, Google's health research business, since its formation in September 2013 and has since been joined by former Genentech/Roche colleagues Hal Barron, David
Hal Barron among four new appointments. Dr Hal Barron has left his role as chief medical officer of Swiss pharma company Roche to join Google's recently-launched health research arm ... Dr Barron is one of four new recruits from industry and academia to
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...